Literature DB >> 12626542

Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.

Carsten Wiethe1, Kurt Dittmar, Tracy Doan, Werner Lindenmaier, Robert Tindle.   

Abstract

Up-regulation of receptor-ligand pairs during interaction of an MHC-presented epitope on dendritic cells (DCs) with cognate TCR may amplify, sustain, and drive diversity in the ensuing T cell immune response. Members of the TNF ligand superfamily and the TNFR superfamily contribute to this costimulatory molecule signaling. In this study, we used replication deficient adenoviruses to introduce a model tumor-associated Ag (the E7 oncoprotein of human papillomavirus 16) and the T cell costimulatory molecule 4-1BBL into murine DCs, and monitored the ability of these recombinant DCs to elicit E7-directed T cell responses following immunization. Splenocytes from mice immunized with DCs expressing E7 alone elicited E7-directed effector and memory CTL responses. Coexpression of 4-1BBL in these E7-expressing DCs increased effector and memory CTL responses when they were used for immunization. 4-1BBL expression up-regulated CD80 and CD86 second signaling molecules in DCs. We also report an additive effect of 4-1BBL and receptor activator of NF-kappa B/receptor activator of NF-kappa B ligand coexpression in E7-transduced DC immunogens on E7-directed effector and memory CTL responses and on MHC class II and CD80/86 expression in DCs. Additionally, expression of 4-1BBL in E7-transduced DCs reduced nonspecific T cell activation characteristic of adenovirus vector-associated immunization. The results have generic implications for improved or tumor Ag-expressing DC vaccines by incorporation of exogenous 4-1BBL. There are also specific implications for an improved DC-based vaccine for human papillomavirus 16-associated cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626542     DOI: 10.4049/jimmunol.170.6.2912

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

3.  Application of a reversible immortalization system for the generation of proliferation-controlled cell lines.

Authors:  Tobias May; Werner Lindenmaier; Dagmar Wirth; Peter P Mueller
Journal:  Cytotechnology       Date:  2005-11-30       Impact factor: 2.058

4.  4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Cosette Dechant; Xiuyu Cui; Pakawat Chongsathidkiet; Daniel Wilkinson; Jessica Waibl-Polania; Luis Sanchez-Perez; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

Review 5.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 6.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

7.  The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus.

Authors:  Kuang Youlin; Weng Xiaodong; Liu Xiuheng; Chen Zhiyuan; Zhu Hengcheng; Chen Hui; Jiang Botao
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

8.  Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Authors:  Sumita Ganguly; Jinyan Liu; Vinod B Pillai; Robert S Mittler; Rama Rao Amara
Journal:  Vaccine       Date:  2009-11-26       Impact factor: 3.641

9.  Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Authors:  Thomas Schwaab; Adrian Schwarzer; Benita Wolf; Todd S Crocenzi; John D Seigne; Nancy A Crosby; Bernard F Cole; Jan L Fisher; Jill C Uhlenhake; Diane Mellinger; Cathy Foster; Zbigniew M Szczepiorkowski; Susan M Webber; Alan R Schned; Robert D Harris; Richard J Barth; John A Heaney; Randolph J Noelle; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

10.  Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses.

Authors:  Jacob Bukczynski; Tao Wen; Kim Ellefsen; Jack Gauldie; Tania H Watts
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.